Shire hires ex-Merck exec
Executive Summary
Former Merck KGaA global ethical pharmaceuticals president Matthew Emmens named CEO of Shire effective March 19. Emmens succeeds Rolf Stahel, who announced his intention to leave the company in October. Emmens previously spent 19 years at U.S. Merck & Co., and was CEO of Astra Merck joint venture...
You may also be interested in...
Shire establishes U.S. headquarters
U.K.-based Shire sets up North American headquarters in Wayne, Penn. and plans to close its facilities in Rockville, Md. and Newport, Ky. The new facility will house about 400 employees by end of 2005. Establishing a U.S. headquarters was one step in a streamlining effort announced by CEO Matthew Emmens shortly after he joined the company this spring (1"The Pink Sheet" March 17, 2004, In Brief)...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.